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Dear Editor,
The paper by Henry et al. published by Supportive Care in
Cancer comparing efficacy of denosumab versus zoledronic
acid in patients with bone metastases of advanced solid tu-
mours [1] comes to integrate the original reports of three
pivotal large randomized phase 3 trials [2–4], the publication
by Saad et al. about osteonecrosis of the jaw (ONJ) in those
three trials [5], and the combined outcome analysis by Lipton
et al. [6].
Henry et al. [1] reported outcomes of the single trial con-
ducted on patients with solid tumours (except breast or pros-
tate cancers, object of other two trials) [2, 3], excluding
patients with multiple myeloma: This ad hoc analysis con-
firmed the superiority of denosumab in delaying or preventing
skeletal-related events [1]. Amongst side effects, after a me-
dian (Q1, Q3) time on study of 6.7 (3.2, 13.0) and 6.4 (3.1,
12.9)months in the two groups, ONJ was reported in six
denosumab arm patients (0.8 %) and in nine zoledronic acid
arm patients (1.1 %).
We wish to underline some sparse data reported in the cited
papers, focusing attention on occurrence of ONJ in patients
with renal cell cancer (RCC) included in the trial.
In the summary ONJ analysis [5] of the above-mentioned
three randomized trials comparing zoledronic acid and
denosumab in patients with several cancer types and conduct-
ed between 2006 and 2009, it appears that an “Oral Event
Identified as Potential ONJ”was registered in 276 patients out
of 5,723 (4.8 %). Finally, cases of positively adjudicated ONJ
according to very strict criteria were only 89 (1.6 %)—37
(1.3 %) on zoledronic acid and 52 (1.8 %) on denosumab.
Notably, in the three trials, there were 14 ONJ cases among
464 patients treated with an antiresorptive agent (zoledronic
acid or denosumab) and antiangiogenic agents (3.0 %) versus
75 ONJ cases among 5,259 patients receiving zoledronic acid
or denosumab without any antiangiogenic agents (1.4 %) [5]:
This kind of data seems to enforce recent literature data
suggesting possible higher ONJ risk from combination of
antiresorptive and antiangiogenic agents [7, 8].
According to the paper by Saad et al. [5], among 89 total
adjudicated ONJ patients (treated either with zoledronic acid
or denosumab) there were six RCC patients, out of a total
number of enrolled RCC patients of 155 [1, 4]. This 6/155
(3.9 %) ONJ frequency in RCC patients is more than twice as
high, if compared with the entire patient population (1.6 %).
In recent years, bone metastatic RCC patients received
routinely targeted therapy, as monoclonal anti-VEGF anti-
body (bevacizumab), tyrosin-kinase inhibitors (sunitinib, so-
rafenib, pazopanib), mTOR inhibitors (temsirolimus, everoli-
mus). Several types of recent reports suggest a relatively high
ONJ risk in RCC patients after a combination of
bisphosphonates (mostly zoledronic acid) and antiangiogenic
agents (mostly sunitinib) [9–12].
The question is: could the antiangiogenic treatment have
played a role in the 3.9 %ONJ rate among RCC patients in the
trial illustrated by Henry et al.? Unfortunately, according to
the reports of the trial [1, 4], it is neither arguable howmany of
those six RCC patients developing ONJ had received
antiangiogenic agents, nor which bone antiresorptive agent
was administered.
Furthermore, we can extrapolate from the cited reports of
the trials [2–5] that, among 21 ONJ adjudicated cases, an
antiangiogenic drug had been administered in six out of
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eleven ONJ patients in the zoledronic acid arm versus one out
of ten ONJ patients in the denosumab arm. This seems to
suggest a possible higher risk of ONJ in patients who had
received zoledronic acid together with an antiangiogenic
agent, in comparison to the association of denosumab with a
targeted therapy.
We think that the details of the treatment received by RCC
patients in the trial reported by Henry et al. [1, 4] (preferably if
updated with longer follow-up) would be of value to clarify
the role of a targeted therapy (i.e., antiangiogenic drugs)
together with zoledronic acid or denosumab in developing
ONJ.
Disclosure/conflict of interest None.
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